Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ret finger protein-like 1 (RFPL1) is a member of the RING-B30 protein family, characterized by a tripartite structure containing a RING finger domain, coiled-coil region, and B30-2 domain[3]. The RING finger motif enables it to act as an E3 ubiquitin ligase, catalyzing the transfer of ubiquitin to substrate proteins, leading to their proteasomal degradation[4][1]. RFPL1 is predicted to negatively regulate the G2–M cell cycle transition, possibly by promoting the proteasomal degradation of cyclin B1 (CCNB1) and cyclin-dependent kinase 1 (CDK1), thus preventing their accumulation during interphase[1][6]. It localizes to the cytoplasm. There are paralogs (RFPL2, RFPL3), and RFPL1 is associated with genetic conditions such as oculomotor nerve paralysis, but no clear evidence establishes its use as a therapeutic drug target. The broader RING finger protein family plays diverse biological roles—including ubiquitination, cell cycle regulation, and immune signaling—with involvement in multiple diseases, but RFPL1 itself does not appear to be a validated therapeutic target at this time[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ret finger protein-like 1 (RFPL1).